AstraZeneca vaccine approved for use in Australia, CSL (ASX:CSL) share price up

The CSL Limited (ASX:CSL) share price rose 2% after the AstraZeneca – Oxford University COVID-19 vaccine was approved in Australia.

| More on:
covid vaccine stocks represented by row of vials labelled covid vaccine

Image source: Getty Images

The CSL Limited (ASX: CSL) share price climbed 2% today after the AstraZeneca – Oxford University COVID-19 vaccine was approved for use in Australia.

According to reporting by the Australian Financial Review, the provisional approval will mean that adults who are 18 or older will be able to take two doses of the drug, between four to twelve weeks apart.

The Australian federal government has ordered almost 54 million doses of the vaccine, with CSL to start manufacturing within the country from the end of next month. CSL has been tasked with manufacturing 50 million doses. 

One of the main benefits of the Oxford University – AstraZeneca COVID-19 vaccine is that it can be held in normal refrigerators. The Pfizer COVID-19 vaccine needs to be stored at -70C.

Some of the first Australians to receive the vaccine will be border workers, health workers involved in the fight against COVID-19, and people who are involved in aged care settings.

What is CSL’s involvement in the COVID-19 vaccine?

In regards to the COVID-19 vaccine, CSL announced back in September 2020 that it had signed an agreement with the Australian federal government.

CSL will manufacture the COVID-19 vaccine from its Australian facilities, as well as manufacturing the company’s vital core therapies.

The Australian government has provided funding to support CSL’s readiness to manufacture the Oxford University – AstraZeneca vaccine, which has expanded Australia’s on-shore vaccine manufacturing capabilities.

The funding is being used to establish at-risk components required to produce the commercial manufacture of the recombinant vector-based COVID-19 vaccine, including funding for specialised equipment, recruitment training and redeployment of personnel and retooling and reconfiguration of existing manufacturing facilities to ‘good manufacturing practice’ standards.

At the time of the announcement of the deal with the federal government, CSL CEO and managing director Paul Perreault said:

“Acknowledging that CSL is the only company in Australia with manufacturing facilities capable of producing this vaccine, we thank the Australian government for their support, ensuring Australia has access to onshore COVID-19 vaccine production and supply. Our facilities will require modifications in order to fulfil the compliance requirements for working with vector-based vaccines, as well as the addition of skilled personnel and further capital investment.”

Mr Perreault also spoke of the company’s prior involvement in manufacturing vaccines: “CSL’s history is linked with a commitment to Australia’s public health needs. In 1918 we produced a vaccine for the Spanish influenza pandemic, in 2009 we developed a vaccine for the swine flu pandemic, and now we are incredibly proud to use our skills, technology and facilities to help ensure Australia – and the world – can access a COVID-19 vaccine.”

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Coronavirus News

Man with his hand on his face looking at a falling share price chart on a tablet.
Share Market News

ASX 200 stocks dive 2.4% in worst trading day since Ukraine crisis hit

It's not a good start to the week for the market.

Read more »

A woman looks nervous and uncertain holding a hand to her chin while looking at a paper cut out of a plane that she's holding in her other hand. representing the falling Air New Zealand share price today
Travel Shares

Borders just reopened so why is the Flight Centre (ASX:FLT) share price falling today?

Experts believe it may take several years for tourism levels to rebound to pre-pandemic numbers.

Read more »

A worker in hi vis gear holds his hand up saying no.
Coronavirus News

Own BHP (ASX:BHP) shares? Here’s how the ASX 200 miner is battling COVID

Mining unions have not generally supported mandatory vaccinations.

Read more »

Female worker sitting desk with head in hand and looking fed up
Coronavirus News

Here’s what Rio Tinto (ASX:RIO) boss says is ‘causing some challenges’ right now

The Omicron variant is spreading in Western Australia.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Coronavirus News

Why are ASX COVID test shares climbing today?

COVID-19 tests are in focus again today.

Read more »

a girl stands in an apple orchard holding two red apples in raised arms with a happy, celebratory look on her face with a large smile and a pretty country background to the picture.

CBA reveals the Australian economy’s leading state amid COVID surge

The states and territories have all been impacted by the pandemic.

Read more »

Rapid Antigen Test taking place.
Share Market News

Why is Ellume hitting headlines today?

Brisbane-based diagnostics developer Ellume is back in the headlines.

Read more »

A woman looks quizzical as she looks at a graph of the share market.
Share Market News

Inghams (ASX:ING) share price sinks as Omicron bites

Inghams shares are down as COVID hurts its operations.

Read more »